polypid®, a specialty pharmaceutical company, develops and manufactures products based on its plex™ technology. so far, 70 patients have been treated in clinical trials with polypid’s anti-infection products demonstrating safety and efficacy. polypid is in the process of submitting its lead product for phase-iii trial in the us and eu. plex™ is able to optimize drugs' therapeutic performance and clinical outcomes. plex™-based protected drug reservoir is implanted directly into the body’s target area thus enabling prolonged delivery of drugs, over periods ranging from days to several months. polypid’s pipeline focuses on 3 products: d-plex™ - intended for prevention and treatment of surgical infections caused by bacteria. its effectiveness is currently being tested in patients undergoing open-heart surgery, with a view to preventing infections that may occur following surgery. the product is currently undergoing clinical studies at several medical centers. bonypid®-1000 - designed to e
Company profile
Ticker
PYPD
Exchange
Website
CEO
Amir Weisberg
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
PYPD stock data
Latest filings (excl ownership)
S-8
Registration of securities for employees
6 Mar 24
20-F
2023 FY
Annual report (foreign)
6 Mar 24
6-K
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
14 Feb 24
6-K
PolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 Trial
14 Feb 24
EFFECT
Notice of effectiveness
14 Feb 24
CORRESP
Correspondence with SEC
12 Feb 24
UPLOAD
Letter from SEC
9 Feb 24
F-3
Shelf registration (foreign)
1 Feb 24
D
$35.01 mm in equity / options / securities to be acquired, sold $35.01 mm, 20 investors
22 Jan 24
6-K
PolyPid Announces Private Placement for $16 Million in Gross Proceeds
5 Jan 24
Transcripts
PYPD
Earnings call transcript
2023 Q4
14 Feb 24
PYPD
Earnings call transcript
2023 Q3
8 Nov 23
PYPD
Earnings call transcript
2023 Q2
9 Aug 23
PYPD
Earnings call transcript
2023 Q1
10 May 23
PYPD
Earnings call transcript
2022 Q4
8 Feb 23
PYPD
Earnings call transcript
2022 Q2
11 Aug 22
PYPD
Earnings call transcript
2022 Q1
11 May 22
PYPD
Earnings call transcript
2021 Q4
9 Feb 22
PYPD
Earnings call transcript
2021 Q2
11 Aug 21
PYPD
Earnings call transcript
2021 Q1
12 May 21
Latest ownership filings
SC 13G
Rosalind Advisors, Inc.
1 Mar 24
SC 13G
Centaurus Investments Ltd
20 Sep 23
SC 13G/A
Aurum Ventures M.K.I. Ltd.
17 May 23
SC 13G/A
Gabriel Capital Management Ltd.
10 Feb 23
SC 13G/A
Aurum Ventures M.K.I. Ltd.
15 Jul 22
SC 13G/A
Aurum Ventures M.K.I. Ltd.
24 Feb 22
SC 13G
Aurum Ventures M.K.I. Ltd.
24 Feb 22
SC 13G/A
Gabriel Capital Management Ltd.
10 Feb 22
SC 13G
Gabriel Capital Management Ltd.
12 Feb 21
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 3 |
Opened positions | 1 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 4.74 mm |
Total shares | 12.51 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Aurum Ventures M.K.I. | 7.84 mm | $3.10 mm |
Centaurus Investments | 4.22 mm | $1.64 mm |
Gabriel Capital Management | 447.91 k | $0.00 |
News
PolyPid Q4 EPS $(3.97) Misses $(3.58) Estimate
14 Feb 24
Earnings Scheduled For February 14, 2024
14 Feb 24
PolyPid Reports Enrollment Of The 100th Patient In Ongoing SHIELD II Phase 3 Trial
12 Feb 24
Why Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session
5 Jan 24
PolyPid Announces $16.2M Private Placement Of 3,371,312 Shares At $4.81/Share
4 Jan 24
Press releases
PolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 Trial
12 Feb 24
PolyPid to Report Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights on February 14, 2024
31 Jan 24
PolyPid Announces Private Placement for $16 Million in Gross Proceeds
4 Jan 24